Cost-effectiveness analysis of NEPA, a fixed-dose combination of netupitant and palonosetron, for the prevention of highly emetogenic chemotherapy-induced nausea and vomiting: an international perspective.

Autor: Nilsson J; ICON Plc, Stockholm, Sweden. jonas.e.nilsson@hotmail.com., Piovesana V; Helsinn Healthcare SA, Lugano, Switzerland., Turini M; Helsinn Healthcare SA, Lugano, Switzerland., Lezzi C; Helsinn Healthcare SA, Lugano, Switzerland., Eriksson J; ICON Plc, Stockholm, Sweden., Aapro M; Genolier Cancer Centre, Clinique de Genolier, Genolier, Switzerland.
Jazyk: angličtina
Zdroj: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer [Support Care Cancer] 2022 Nov; Vol. 30 (11), pp. 9307-9315. Date of Electronic Publication: 2022 Sep 08.
DOI: 10.1007/s00520-022-07339-1
Abstrakt: Purpose: The aim of this study was to assess the cost-effectiveness of NEPA, a fixed-dose combination of oral netupitant (300 mg) and palonosetron (0.5 mg), compared to available treatments in Spain after aprepitant generic introduction in the market, and to discuss results in previously performed analyses in different wordwide settings.
Methods: A Markov model including three health states, complete protection, complete response at best and incomplete response, was used to evaluate the cost-effectiveness of NEPA versus common treatment options in Spain during 5 days after chemotherapy. Incremental costs including treatment costs and treatment failure management cost as well as incremental effects including quality adjusted life days (QALDs) and emesis-free days were compared between NEPA and the comparator arms. The primary outcomes were cost per avoided emetic event and cost per QALDs gained.
Results: NEPA was dominant (more effective and less costly) against aprepitant combined with palonosetron, and fosaprepitant combined with granisetron, while, compared to generic aprepitant plus ondansetron, NEPA showed an incremental cost per avoided emetic event of €33 and cost per QALD gained of €125.
Conclusion: By most evaluations, NEPA is a dominant or cost-effective treatment alternative to current antiemetic standards of care in Spain during the first 5 days of chemotherapy treatment in cancer patients, despite the introduction of generics. These results are in line with previously reported analyses throughout different international settings.
(© 2022. The Author(s).)
Databáze: MEDLINE
Externí odkaz: